Medicare Enrolled
Dr. Jane Chawla, MD
Medical Oncology · Austin, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chawla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chawla? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chawla
Dr. Jane Chawla is a medical oncology in Austin, TX, with 18 years in practice. Based on federal Medicare data, Dr. Chawla performed 105,551 Medicare services across 3,646 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chawla received a total of $524 from 11 pharmaceutical and/or device companies across 15 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chawla is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 9% volume in TX$ $524 industry payments
Medicare Practice Summary
Medicare Utilization ↗105,551
Medicare services
Top 9% in TX for medical oncology
3,646
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,864 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) | 15,150 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 11,800 | $43 | $137 |
| Iron sucrose injection (Venofer) | 11,300 | $0 | $2 |
| Iron infusion (Feraheme) | 10,200 | $0 | $5 |
| Paclitaxel chemotherapy injection | 10,182 | $0 | $8 |
| Oxaliplatin chemotherapy injection | 9,300 | $0 | $33 |
| Darbepoetin injection (Aranesp) for anemia | 8,840 | $2 | $20 |
| Contrast dye for imaging (iodine-based) | 7,550 | $0 | $3 |
| Anti-nausea injection (aprepitant) | 3,510 | $1 | $8 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $19 | $67 |
| Dexamethasone injection (steroid) | 1,955 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,500 | $1 | $114 |
| Injection, bevacizumab, 10 mg | 1,230 | $57 | $196 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,210 | $21 | $181 |
| Injection, granisetron hydrochloride, 100 mcg | 820 | $0 | $24 |
| Complete blood count (CBC) with differential | 554 | $8 | $36 |
| Blood draw (venipuncture) | 541 | $8 | $20 |
| Injection of additional new drug or substance into vein | 474 | $13 | $108 |
| Comprehensive metabolic blood panel | 456 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 362 | $2 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 347 | $108 | $707 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 324 | $82 | $1,348 |
| Injection, carboplatin, 50 mg | 322 | $2 | $300 |
| Office visit, established patient (30-39 min) | 310 | $95 | $368 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 264 | $3 | $373 |
| Immunoglobulin level test | 219 | $9 | $56 |
| Injection, magnesium sulfate, per 500 mg | 192 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 186 | $51 | $313 |
| Administration of chemotherapy into vein, each additional hour | 181 | $23 | $161 |
| Injection, zoledronic acid, 1 mg | 181 | $6 | $431 |
| Lactate dehydrogenase (enzyme) level | 178 | $6 | $31 |
| Office visit, established patient (20-29 min) | 178 | $56 | $250 |
| Measurement of immunoglobulin light chains | 170 | $17 | $60 |
| Ferritin level test (iron stores) | 153 | $13 | $60 |
| Administration of additional new drug or substance into vein, 1 hour or less | 144 | $53 | $344 |
| Iron level test | 137 | $6 | $27 |
| Iron binding capacity test | 137 | $9 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 135 | $24 | $157 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 128 | $60 | $211 |
| Drug injection, under skin or into muscle | 120 | $11 | $96 |
| Injection, diphenhydramine hcl, up to 50 mg | 119 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 105 | $16 | $94 |
| Infusion, normal saline solution , 1000 cc | 92 | $2 | $19 |
| Hospital follow-up visit, moderate complexity | 91 | $61 | $247 |
| Unclassified drugs | 83 | $1 | $8 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 83 | $129 | $3,675 |
| Microscopic examination for white blood cells with manual cell count | 82 | $4 | $22 |
| Complete blood count (CBC), automated | 82 | $6 | $34 |
| Magnesium level test | 79 | $7 | $29 |
| CT scan of abdomen and pelvis with contrast | 64 | $190 | $1,067 |
| Ct scan of chest with contrast | 63 | $47 | $821 |
| Office visit, established patient, complex (40-54 min) | 56 | $138 | $496 |
| Carcinoembryonic antigen (cea) protein level | 54 | $19 | $99 |
| Reticulated (young) platelet measurement | 51 | $35 | $143 |
| Red blood count automated, with additional calculations | 49 | $5 | $26 |
| Protein measurement, serum | 46 | $11 | $99 |
| Immunologic analysis technique on serum | 45 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 44 | $22 | $160 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 44 | $25 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 43 | $17 | $100 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 42 | $136 | $500 |
| Administration of additional new drug or substance into vein using push technique | 39 | $46 | $289 |
| New patient office visit (45-59 min) | 38 | $110 | $565 |
| Infusion into a vein for hydration, each additional hour | 37 | $10 | $75 |
| Vitamin B-12 level test | 33 | $15 | $76 |
| Folic acid level test | 32 | $14 | $73 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 32 | $300 | $2,762 |
| Hospital follow-up visit, low complexity | 31 | $36 | $135 |
| Infusion into a vein for hydration, 31-60 minutes | 27 | $27 | $256 |
| Application of on-body injector for under skin injection | 27 | $15 | $96 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $1 | $19 |
| Initial hospital admission, moderate complexity | 25 | $102 | $470 |
| Irrigation of implanted venous access drug delivery device | 24 | $20 | $114 |
| New patient office visit, complex (60-74 min) | 22 | $171 | $709 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 19 | $90 | $657 |
| CT scan of chest, without contrast | 16 | $45 | $686 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 16 | $1,222 | $4,802 |
| Injection of drug or substance into vein | 15 | $31 | $247 |
| Ct scan of abdomen and pelvis without contrast | 13 | $83 | $560 |
| Initial hospital admission, high complexity | 11 | $130 | $694 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 11 | $197 | $700 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.3% high complexity
85.6% medium
4.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$524
Total received (2018-2024)
Avg $87/year across 6 years
Bottom 23% in TX for medical oncology
11
Companies
15
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$405 (77.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$119 (22.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$121
2023$79
2022$161
2021$120
2019$18
2018$25
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Medtronic, Inc.
$148
Seagen Inc.
$96
Incyte Corporation
$90
Merck Sharp & Dohme Corporation
$42
AstraZeneca Pharmaceuticals LP
$32
PFIZER INC.
$26
Janssen Biotech, Inc.
$25
CTI BioPharma Corp.
$21
Regeneron Healthcare Solutions, Inc.
$17
Celgene Corporation
$14
Gilead Sciences, Inc.
$12
Top 3 companies account for 63.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · DARZALEX · ELIQUIS · KEYTRUDA · LIBTAYO · LYNPARZA · REBLOZYL · SIGNIA · Vonjo
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
28
Per 100K population
2.1
County median income
$97,169
Nearest hospital
NORTHWEST HILLS SURGICAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Chawla is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Chawla experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Chawla performed 15,150 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chawla receive payments from pharmaceutical companies?
Yes. Dr. Chawla received a total of $524 from 11 companies across 15 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chawla's costs compare to other medical oncologys in Austin?
Dr. Chawla's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chawla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Austin
Browse medical oncologys in Austin ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc..
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc..
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology